Orthofix Medical Inc. (NASDAQ:OFIX) CAO Sells $13,644.93 in Stock

Orthofix Medical Inc. (NASDAQ:OFIX) CAO Geoffrey C. Gillespie sold 767 shares of the business’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $17.79, for a total value of $13,644.93. Following the completion of the sale, the chief accounting officer now directly owns 39,323 shares of the company’s stock, valued at $699,556.17. The trade was a 1.91 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Orthofix Medical Trading Down 1.5 %

NASDAQ:OFIX opened at $18.20 on Friday. The company has a current ratio of 2.39, a quick ratio of 1.11 and a debt-to-equity ratio of 0.25. The stock’s 50 day simple moving average is $18.00 and its 200-day simple moving average is $17.17. Orthofix Medical Inc. has a 12-month low of $12.08 and a 12-month high of $20.73. The firm has a market cap of $695.49 million, a P/E ratio of -5.81 and a beta of 1.10.

Orthofix Medical (NASDAQ:OFIX) last announced its quarterly earnings data on Thursday, November 7th. The medical device company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.57). Orthofix Medical had a negative net margin of 15.18% and a negative return on equity of 21.25%. The firm had revenue of $196.61 million during the quarter, compared to analyst estimates of $196.60 million. During the same period in the prior year, the firm posted ($0.77) earnings per share. Equities analysts anticipate that Orthofix Medical Inc. will post -2.81 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Stifel Nicolaus raised Orthofix Medical from a “hold” rating to a “buy” rating and lifted their price target for the stock from $18.00 to $24.00 in a research report on Friday, November 8th. StockNews.com raised shares of Orthofix Medical from a “hold” rating to a “buy” rating in a report on Friday, January 31st. Canaccord Genuity Group initiated coverage on shares of Orthofix Medical in a research note on Wednesday, January 22nd. They set a “buy” rating and a $24.00 price target for the company. Finally, Roth Mkm restated a “buy” rating and issued a $22.00 price objective (up from $20.00) on shares of Orthofix Medical in a research note on Friday, November 8th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, Orthofix Medical presently has an average rating of “Moderate Buy” and an average price target of $23.33.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in OFIX. Inceptionr LLC acquired a new stake in Orthofix Medical in the fourth quarter valued at about $279,000. Raymond James Financial Inc. acquired a new stake in shares of Orthofix Medical in the 4th quarter valued at approximately $1,003,000. Victory Capital Management Inc. boosted its stake in shares of Orthofix Medical by 2.9% in the fourth quarter. Victory Capital Management Inc. now owns 66,675 shares of the medical device company’s stock valued at $1,164,000 after buying an additional 1,868 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Orthofix Medical by 4.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 339,531 shares of the medical device company’s stock worth $5,928,000 after acquiring an additional 14,724 shares during the period. Finally, Versor Investments LP purchased a new position in Orthofix Medical in the fourth quarter worth $499,000. 89.76% of the stock is currently owned by institutional investors and hedge funds.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.